2ME2 is currently in clinical trials for cancer, as well as in preclinical development for inflammatory disorders.
The patents grant EntreMed intellectual property protection for 2ME2 and its derivatives in oncology and a broad range of non-oncology indications, including inflammatory disorders, immune disorders, cardiovascular disorders, and rheumatoid arthritis.
2ME2 is a novel anticancer agent, which is part of a next generation of antimitotic cancer drugs that bind to tubulin and work through multiple cellular pathways. 2ME2 can attack tumors on multiple fronts — directly by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells (mitosis), by inducing programmed cell death (apoptosis), and by blocking blood vessels that feed tumors (angiogenesis inhibition).
James Burns, EntreMed president & CEO, commented, “EntreMed is focused on the development of a new generation of small molecule drugs for the treatment of cancer and inflammatory disorders by attacking disease cells directly and the blood vessels that nourish them. These patents strengthen our position in next generation tubulin and angiogenesis inhibitors for the treatment of cancer and expand the range of indications for our lead anti- angiogenic agents.”